Related Experiment Video
Updated: Aug 8, 2026

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
Published on: May 5, 2023
Epigenetic silencing of 14-3-3sigma in cancer
Dmitri Lodygin1, Heiko Hermeking
1Molecular Oncology, Independent Max-Planck Research Group, Max-Planck-Institute of Biochemistry, Martinsried, Munich, Germany.
Abstract:
The 14-3-3sigma gene is a direct target of the p53 tumor suppressor and its product inhibits cell cycle progression. Recently, a proteomic analysis revealed that 14-3-3sigma regulates additional cellular processes relevant to carcinogenesis, as migration and MAP-kinase signalling. The expression of 14-3-3sigma is down-regulated by CpG methylation in several types of human cancer, among them prostate, lung, breast and several types of skin cancer. The epigenetic inactivation of 14-3-3sigma occurs at an early stage of tumor development and may allow evasion from senescence and promote genomic instability. In the future the detection of CpG methylation of 14-3-3sigma may be used for diagnostic and prognostic purposes.
Insights
The 14-3-3sigma gene, targeted by p53, is epigenetically silenced in cancers like prostate and breast. This inactivation promotes tumor development and may serve as a diagnostic marker.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- The 14-3-3sigma gene, a direct target of the p53 tumor suppressor, plays a role in cell cycle regulation.
- Proteomic analysis indicates 14-3-3sigma also influences carcinogenesis-related processes like cell migration and MAP-kinase signaling.
- Down-regulation of 14-3-3sigma expression via CpG methylation is observed in various human cancers, including prostate, lung, breast, and skin cancers.
Purpose of the Study:
- To investigate the role of 14-3-3sigma in carcinogenesis.
- To understand the mechanism of 14-3-3sigma down-regulation in cancer.
- To explore the potential diagnostic and prognostic utility of 14-3-3sigma CpG methylation.
Main Methods:
- Gene expression analysis.
- Proteomic analysis.
- CpG methylation analysis.
Main Results:
- 14-3-3sigma expression is down-regulated by CpG methylation in multiple human cancers.
- Epigenetic inactivation of 14-3-3sigma occurs early in tumor development.
- This inactivation may facilitate evasion from senescence and promote genomic instability.
Conclusions:
- Epigenetic silencing of 14-3-3sigma is a significant event in early carcinogenesis.
- CpG methylation of 14-3-3sigma could serve as a valuable diagnostic and prognostic biomarker for various cancers.
More Related Videos
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
MicroRNAs
MicroRNAs
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
